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S U M M A R Y
Objective: The clinical characteristics and outcomes in cryptococcal meningitis (CM) have been shown to
vary depending on the underlying condition. The purpose of this study was to investigate these
differences in patients with and without hepatitis B virus (HBV) infection.
Methods: We performed a retrospective study at the Third Afﬁliated Hospital of Sun Yat-Sen University
from January 2006 to June 2012. Thirty-two HBV-positive patients and 58 HBV-negative patients were
included.
Results: Among the 90 patients with CM, 32 (35.6%) were HBV-infected. CM occurred in a younger
population in the HBV-positive group, with a higher Charlson comorbidity score than the HBV-negative
group. The HBV-positive group presented with lower initial complaints of visual symptoms, lower
cerebrospinal ﬂuid (CSF) white blood cell counts, lower percentages of the total protein in the CSF
exceeding 0.45 g/l, higher glucose levels in the CSF, a higher percentage of positive results for
Cryptococcus culture in the CSF, more extraneural involvement sites, and a higher proportion of normal
brain images than the HBV-negative group. Factors for a poor prognosis in the HBV-positive group
included liver cirrhosis and HBV DNA >103 copies/ml. In the HBV-uninfected group, lower glucose in the
CSF and hydrocephalus were the indicators of an unsatisfactory outcome.
Conclusions: Certain clinical features of CM were found to be signiﬁcantly different between HBV-
infected and HBV-uninfected patients, including age and initial laboratory ﬁndings, as well as the
indicators of an unsatisfactory outcome. Host defense defects in the HBV-infected group may lead to a
lower intensity of inﬂammation in the pathogenesis of CM compared with the HBV-uninfected patients
and may account for these divergences between the two groups.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Cryptococcal meningitis (CM) is a common opportunistic
infection and is caused by Cryptococcus neoformans, which can* Corresponding authors.
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http://dx.doi.org/10.1016/j.ijid.2013.11.017be isolated from the environment.1 Risk factors for cryptococcal
infection include the following: infection with HIV, liver cirrhosis,
diabetes mellitus, malignancies, and corticosteroid use; however
the disease may also occur in immunocompetent hosts who are
without any apparent underlying disease.2
Infection with the hepatitis B virus (HBV) severely affects
individuals worldwide, and this virus is a major cause of liver
cirrhosis, which is considered an important risk factor for
cryptococcal infection.3 Without early appropriate therapy, CM
is a uniformly fatal disease. Therefore rapid recognition, diagnosis,
and treatment are necessary to decrease the mortality. However,
there are signiﬁcant divergences in the clinical manifestations
because of different underlying conditions. Notable differences inociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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well documented in the recent literatures.4–6 Nevertheless, the
presentation of CM with HBV infection has not been reported
previously.
In this retrospective study, we aimed to compare the clinical
presentations, laboratory data, radiographic ﬁndings, and out-
comes of CM between HBV-positive and HBV-negative patients
with CM.
2. Methods
2.1. Patients and deﬁnitions
We retrospectively reviewed the medical records of patients
with CM admitted to the Third Afﬁliated Hospital of Sun Yat-Sen
University in Guangzhou, China, from January 2006 to June 2012.
Ninety patients were included in this study. The cryptococcal
antigen test was not available at the Third Afﬁliated Hospital of Sun
Yat-Sen University, so CM was diagnosed in the presence of clinical
features of meningitis along with isolation of C. neoformans from
cerebrospinal ﬂuid (CSF) culture or a positive CSF India ink stain.
The diagnosis of all patients with chronic hepatitis B conformed to
the guidelines previously outlined for the prevention and
treatment of chronic hepatitis B.7
All selected patients had been in hospital for the ﬁrst onset and
were divided into an HBV-positive and an HBV-negative group.
Patients were excluded from the study for the following reasons:
(1) if antiretroviral therapy for HBV infection had been received
prior to hospital admission; (2) if antifungal therapy had been
received prior to admission; (3) if the patient had recurrent CM. A
standardized case collection form was used to record age, sex,
underlying diseases, Charlson comorbidity score, initial presenta-
tions, time from initial symptoms to diagnosis, laboratory data,
radiographic ﬁndings, and in-hospital mortality. Risk factors for a
poor outcome were assessed between these two groups.
This study was approved by the Ethics Committee of the Third
Afﬁliated Hospital of Sun Yat-Sen University (200733) and was in
compliance with the Declaration of Helsinki. All subjects gave
informed consent to participate in this study.
2.2. Laboratory studies
HBV DNA was measured by real-time PCR (Applied Biosystems,
Foster City, CA, USA). HBV DNA >103 copies/ml was considered a
positive load.8 HBV-M was determined using an automated
immunoassay system (1235; Perkin-Elmer, Waltham, MA, USA).
Ultrasonography was performed to identify liver cirrhosis. CSF was
routinely sent to the laboratory for determination of the complete
white blood cell (WBC) count and glucose and protein levels, India
ink stain, and cultures. Urine, feces, phlegm, pus, lung, and/or other
biopsy tissues were collected and submitted to culture when
indicated. All images, including chest ﬁlms, computed tomography
(CT) and magnetic resonance imaging (MRI) scans and CT images of
the brain were analyzed.
2.3. Treatment strategies and outcome
Antifungal therapy was initiated as soon as the diagnosis was
microbiologically conﬁrmed. The induction treatment included
amphotericin B, lipid amphotericin B infusion, or oral ﬂuconazole
(either combined with ﬂucytosine or alone), followed by ﬂucona-
zole as maintenance treatment, which is consistent with the
treatment recommended in previous studies.9,10 The duration of
treatment was individualized according to the patient’s response
and the decision of the attending physician. Therapeutic outcomes
were evaluated according to the deﬁnitions of Diamond andBennett, as follows:11 (1) ‘cured’ if there was no reappearance of
symptoms, two sequential negative CSF cultures for C. neoformans
with at least a 2-week interval, and at least 12 months after
discontinuation of antifungal therapy; (2) ‘improved’, with the
same deﬁnition as for ‘cure’, but the last examination or death
occurred within a year; (3) ‘relapse’, with the same deﬁnition as for
‘improved’, but with the reappearance of symptoms with CSF
culture/India ink proof after therapy had been stopped; (4) ‘fail’ if
death occurred due to the ﬁrst treated CM; and (5) ‘indeterminate’
if death occurred due to causes other than CM and the treatment
course was incomplete. The outcomes were further classiﬁed into a
satisfactory group (cured or improved) and an unsatisfactory
group (death, relapse, or indeterminate) in accordance with
previous studies.11–13
Repeated lumbar punctures and temporary drains, lumbar
drains, or external ventricular drains for the control of increased
intracranial pressure (IICP) were also analyzed. Information on
permanent shunts for long-term CSF drainage was collected
separately.
2.4. Statistical analysis
Continuous data were presented as the mean  standard
deviation or range. Continuous variables were analyzed using the
Student’s t-test and categorical variables were analyzed using the
Chi-square test or Fisher’s exact test if any expected value was below
ﬁve. Kaplan–Meier analysis was used to obtain the survival curves. A
p-value of <0.05 was considered statistically signiﬁcant.
For the outcome analysis, clinical presentations, laboratory
data, and treatment methods were all analyzed as factors using
univariate and multivariate analyses in both groups. Variables
with p < 0.05 when analyzed by univariate logistic regression were
entered into a further multivariate analysis with forward stepwise
regression, leaving only variables with p < 0.05. All analyses were
two-sided and performed using SPSS version 13.0 software (SPSS
Inc., Chicago, IL, USA).
3. Results
3.1. Demographic data
Ninety patients with CM were identiﬁed during the study
period. Of these 90 patients, 32 (35.6%) were HBV-infected. The
demographic details and initial clinical symptoms and laboratory
data of these patients with and without HBV are shown in Tables 1
and 2.
Compared to the HBV-uninfected group, those who suffered
from HBV were younger (mean age 32 vs. 47 years; p = 0.015). HBV
reactivation could be conﬁrmed by an increase in serum HBV DNA
level exceeding 1000 copies/ml. In the present study, 19 of 32
patients (59.4%) had HBV reactivation. There was no signiﬁcant
difference in underlying diseases between the HBV-positive and
HBV-negative groups, except for liver cirrhosis, which was only
found in the former group (31.3% vs. 0%, p < 0.001). All enrolled
patients tested negative for anti-HIV antibodies. We also found no
signiﬁcant difference in the initial presentations between HBV-
positive and HBV-negative patients, except visual symptoms,
which were more frequent in the latter group (3.1% vs. 22.4%,
p = 0.016). The most common initial symptoms were headache
(90%), fever (54.4%), and vomiting (35.6%). The in-hospital
mortality was 6.2% for HBV-positive patients and 10.3% for
HBV-negative patients in terms of day 90 mortality (p = 0.513).
The Charlson comorbidity score was signiﬁcantly higher among
the HBV-infected patients than among the HBV-uninfected
patients (5.0 vs. 3.7, p = 0.007).
Table 1
Patient demographics and characteristics
Variables HBV-infected
(n = 32)
HBV-uninfected
(n = 58)
p-Value
Age, years
Mean  SD 32.2  3.0 46.5  3.2 0.015a
Range 20–67 11–78
Sex, male 27/32 (84.4%) 42/58 (72.4%) 0.199
Predisposing factors
Corticosteroid use 1/32 (3.1%) 3/58 (5.1%) 0.652
Diabetes mellitus 3/32 (9.3%) 5/58 (8.6%) 0.904
Chronic kidney diseases 1/32 (3.1%) 1/58 (1.7%) 0.666
Autoimmune diseases 3/32 (9.3%) 9/58 (15.5%) 0.412
Malignancy 1/32 (3.1%) 1/58 (1.7%) 0.666
Hypertension 3/32 (9.3%) 8/58 (13.7%) 0.540
Hematology and oncology 0/32 (0%) 1/58 (1.7%) 0.455
Neurological diseases 1/32 (3.1%) 10/58 (17.2%) 0.5
Respiratory diseases 4/32 (12.5%) 3/58 (5.1%) 0.214
Cardiovascular diseases 0/32 (0%) 2/58 (3.4%) 0.288
Liver cirrhosis 10/32 (31.2%) 0/58 (0%) <0.001a
Othersb 10/32 (18.7%) 7/58 (12.1%) 0.388
HBV DNA, copies/ml,
mean (range)
1e8 (393–3.36e8) NA NA
Charlson comorbidity index 5.0  1.9 3.7  1.2 0.007a
HBV, hepatitis B virus; SD, standard deviation; NA, not applicable.
a p < 0.05.
b Others included glucose-6-phosphate dehydrogenase deﬁciency, hepatic
fascioliasis.
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As shown in Table 2, the mean CSF WBC count was signiﬁcantly
lower in HBV-infected patients than in the non-HBV-infected
group (mean 40 vs. 85  106/l; p = 0.014). Approximately 28.1% of
the patients with HBV infection had a WBC count below 20  106/l
in the CSF, in contrast to 8.6% of patients without HBV infectionTable 2
Initial clinical symptoms and laboratory dataa
HBV-infe
Fever 19/32 (59
Headache 28/32 (87
Vomiting 13/32 (40
Visual symptoms 1/32 (3.1
Auditory symptoms 1/32 (3.1
Seizures 2/32 (6.2
No neurologic symptoms 1/32 (3.1
Otherc 2/32 (6.2
Time from initial symptoms to diagnosis <1 month 26/32 (81
Opening pressure >300 mmH2O 22/32 (68
CSF WBC count  106/l 40 (2–27
<20 9/32 (28.
CSF protein, g/l 0.74 (0.13
>0.45 20/32 (62
CSF glucose, mmol/l 2.24 (0.01
<4.00 28/32 (87
CSF culture positive 26/32 (81
Serum culture positive 3/32 (9.4
Other site culture positived 7/32 (21.
Chest ﬁlm: mass or nodule lesion 9/32 (28.
Brain images (CT or MRI) 26 
Meningeal enhancement 22/26 (84
Hydrocephalus 13/26 (50
Cerebral infarction 1/26 (3.8
Abscess 1/26 (3.8
Other 1/26 (3.8
Normale 4/26 (15.
HBV, hepatitis B virus; CSF, cerebrospinal ﬂuid; WBC, white blood cell; CT, computed 
a Results are n (%), or mean (range).
b p < 0.05.
c Other initial presentations included dizziness, unilateral decrease in muscle power
d Other site culture positive deﬁned as Cryptococcus neoformans isolated from specime
and wound.
e Normal brain images on CT or MRI were deﬁned as no obvious intracranial lesions(p = 0.015). The patients with HBV infection had higher glucose
levels in the CSF (mean 2.24 vs. 1.55 mmol/l; p = 0.009) and higher
positivity rates for Cryptococcus culture of the CSF (81.2% vs.
53.4%; p = 0.009) and other sites, including urine, feces, phlegm,
pus, lung, and wound (21.9% vs. 6.9%; p = 0.038), than the patients
without HBV. In addition, there was a lower percentage with a total
protein in the CSF exceeding 0.45 g/l (62.5% vs. 82.8%; p = 0.032)
among HBV-positive patients.
A chest X-ray was done for all of the patients. The most common
presentation on chest ﬁlms was a mass lesion. Brain images were
obtained for only 79 patients; meningeal enhancement, hydro-
cephalus, cerebral infarction, and abscess were commonly
revealed. A higher percentage of patients with HBV infection
presented with normal brain images than those without HBV
infection (15.4% vs. 1.9%; p = 0.021).
3.3. Treatment and outcomes
Patients were divided into four groups according to the
therapeutic regimen used, as shown in Table 3; there were no
signiﬁcant differences between the patients in the two groups who
received each regimen. For the management of IICP, temporary
drains, which released the pressure by frequent drainage of small
amounts of CSF several times a day until symptoms improved, was
administrated in three HBV-infected patients and seven HBV-
uninfected patients. For long-term CSF drainage, permanent shunt
devices were inserted in three HBV-infected patients and four
HBV-uninfected patients. Approximately 31.2% of HBV-infected
patients and 25.9% of patients without HBV received adjuvant
corticosteroid therapy.
One HBV-infected patient and one HBV-uninfected patient
were lost to follow-up. Eighty-eight patients were followed up
until death or at least 6 months after discontinuation of antifungalcted HBV-uninfected p-Value
.3%) 30/58 (51.7%) 0.485
.5%) 53/58 (91.4%) 0.557
.6%) 19/58 (32.7) 0.456
%) 13/58 (22.4%) 0.016b
%) 6/58 (10.3%) 0.221
%) 4/58 (6.8%) 0.906
%) 0/58 (0%) 0.356
%) 2/58 (3.4%) 0.537
.3%) 37/58 (63.7%) 0.084
.8%) 33/58 (56.9%) 0.270
8) 85 (2–1600) 0.014b
1%) 5/58 (8.6%) 0.015b
–3.00) 1.18 (0.16–11.75) 0.142
.5%) 48/58 (82.8%) 0.032b
–5.54) 1.55 (0.03–3.68) 0.009b
.5%) 57/58 (98.2%) 0.033b
.2%) 31/58 (53.4%) 0.009b
%) 6/58 (10.3%) 0.883
9%) 4/58 (6.9%) 0.038b
1%) 7/58 (12.1%) 0.057
53
.6%) 43/53 (81.1%) 0.703
%) 21/53 (39.6%) 0.381
%) 7/53 (13.2%) 0.194
%) 3/53 (5.7%) 0.703
%) 5/53 (9.4%) 0.378
4%) 1/53 (1.9%) 0.021b
tomography; MRI, magnetic resonance imaging.
, neck pain, and cough.
ns other than CSF, including any one of the following: urine, feces, phlegm, pus, lung,
 demonstrated.
Table 3
Treatment and mortalitya
Treatment as antifungal therapy HBV-infected HBV-uninfected p-Value
Amphotericin B + ﬂucytosine 19/32 (59.4%) 26/58 (44.8%) 0.645
Lipid amphotericin B + ﬂucytosine 1/32 (3.1%) 2/58 (3.4%) 0.935
Fluconazole alone 3/32 (9.4%) 7/58 (12.1%) 0.697
Fluconazole + ﬂucytosine 9/32 (28.1%) 23/58 (39.7%) 0.077
Treatment for IICP 31/32 (96.7%) 55/58 (94.8%) 0.652
Repeated LP 23/32 (71.9%) 46/58 (79.3%) 0.425
Number of LP 10.0  2.8 11.5  3.2 0.503
Temporary drain 3/32 (9.4%) 7/58 (12.1%) 0.697
Permanent shunt device 3/32 (9.4%) 4/58 (6.9%) 0.674
Adjuvant therapy: corticosteroid 10/32 (31.2%) 15/58 (25.9%) 0.585
In-hospital mortality 2/32 (6.2%) 6/58 (10.3%) 0.513
HBV, hepatitis B virus; IICP, increased intracranial pressure; LP, lumbar puncture;
SD, standard deviation.
a Results are n (%), or mean  SD.
Table 4
Treatment outcomes and sequelaea
HBV-infected HBV-uninfected p-Value
Lost to follow-up 1/32 (3.1%) 1/58 (1.7%) 0.666
Satisfactory outcomes 19/31 (61.3%) 43/57 (75.4%) 0.165
Cure/success 13/31 (41.9%) 30/57 (52.6%) 0.338
Improved 6/31 (19.3%) 13/57 (22.8%) 0.707
Unsatisfactory outcomes 12/31 (38.7%) 14/57 (24.6%) 0.133
Fail 2/31 (6.5%) 6/57 (10.5%) 0.525
Relapse 9/31 (32.3%) 7/57 (12.3%) 0.052
Indeterminate 1/31 (3.2%) 1/57 (1.8%) 0.658
Sequelae 13/29 (44.8%) 25/51 (49.0%) 0.718
Headache 6/29 (20.7%) 10/51 (19.6%) 0.907
Dizziness/vertigo 0/29 (0%) 3/51 (5.9%) 0.146
Hemiparesis 6/29 (20.7%) 2/51 (3.9%) 0.016b
Visual 8/29 (27.6%) 18/51 (35.3%) 0.553
Auditory 7/29 (24.1%) 5/51 (9.8%) 0.072
Seizure 5/29 (17.2%) 4/51 (7.8%) 0.179
HBV, hepatitis B virus.
a Results are n (%).
b p < 0.05.
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patients had an unsatisfactory outcome (Table 4).
In the multivariate analysis, a low CSF glucose level (odds ratio
(OR) 0.197, 95% conﬁdence interval (CI) 0.044–0.890; p = 0.035)
and hydrocephalus (OR 15.209, 95% CI 1.185–195.195; p = 0.037)
were signiﬁcant indicators of an unsatisfactory outcome in the
HBV-uninfected group. The multivariate analysis also demonstrat-
ed liver cirrhosis (OR 14.424, 95% CI 1.449–143.425; p = 0.023) and
an HBV load above 103 copies/ml (OR 13.433, CI 1.251–144.220;
p = 0.032) to be poor prognosis factors for the patients with HBV
infection (Table 5). Kaplan–Meier survival curves for all patients
are shown in Figure 1; no signiﬁcant difference in mortality hazard
was found between the HBV-infected and HBV-uninfected groups
(log-rank test, p = 0.588).
4. Discussion
It is generally known that CM is an opportunistic infection in
immunocompromised patients, but it also occurs in healthy
individuals.4 In this context, diabetes mellitus, corticosteroid
use, autoimmune disease, hypertension, and neurological disease
were the major underlying conditions in patients without HBV. In
the HBV-infected group, 10 of the 32 patients suffered from liver
cirrhosis. However, 17 patients (18.9% of the total enrolled
patients) had no apparent underlying disease, which is consistent
with the results of an earlier report.6 In this report, the incidence of
altered mentation (4.4% of total patients) was signiﬁcantly lower
than that reported in previous publications (20–32% of
patients).14,15
The main ﬁndings of this study are related to certain differences
between HBV-infected and non-HBV-infected patients with CM.
Compared to the HBV-uninfected group, those with HBV wereTable 5
Factors associated with unsatisfactory outcomes after treatment of HBV-infected and H
Variables Univariate analysis 
OR 95% CI 
HBV-uninfected with CM
Age >50 years 4.375 1.193–16.038 
Hypertension 7.407 1.49–36.8 
CSF glucose 0.430 0.222–0.832 
Hydrocephalus 8.250 2.121–32.090 
Number of LP 1.300 1.090–1.549 
Charlson comorbidity index 0.620 0.428–0.898 
HBV infected with CM
Age >50 years 2.140 1.335–54.127 
Liver cirrhosis 7.467 1.385–40.245 
HBV DNA >103 copies/ml 1.928 1.171–40.378 
HBV, hepatitis B virus; OR, odds ratio; CI, conﬁdence interval; CM, cryptococcal menin
a p < 0.05.signiﬁcantly younger and had higher glucose levels in the CSF, a
higher positive rate of Cryptococcus culture in CSF, and more
extraneural involvement. More HBV-uninfected patients pre-
sented with visual symptoms, higher CSF WBC counts, CSF protein
levels above 0.45 g/l, and abnormal brain imaging. The Charlson
comorbidity score was signiﬁcantly higher in the HBV-positive
group, which could be explained by the inherent characteristics of
the scoring system. In addition to the above-mentioned differ-
ences, the indicators of unsatisfactory outcomes were different in
the two groups.
The reasons for the divergences in results between HBV and
non-HBV patients with CM, including age, CSF parameters,
extraneural site involvement, etc., remain unknown, but some
emerging evidence may explain these differences. Cryptococcus
exists ubiquitously in the environment with a worldwide
distribution. It is known that successful host resistance to C.
neoformans depends primarily on cell-mediated immunity.16 For
the host, macrophages are the ﬁrst line of host defense and
complement-mediated phagocytosis is likely to be the primary
initial defense against cryptococcal infection. Complement can
enhance the efﬁcacy of antibody-mediated protection against
cryptococcosis.17 Moreover, the host defense factors against
infection also include cytokines, such as tumor necrosis factor
(TNF)-a and interleukin (IL)-18, as well as antibodies.18 However,
liver disease, such as that caused by HBV infection, may lead to a
number of host defense defects, including impaired cell-mediated
immunity, phagocytic dysfunction, decreased antibodies and
immunoglobulin concentrations, and complement deﬁciency.
The absence of the ﬁrst host defenses could account for theBV-uninfected patients with cryptococcal meningitis
Multivariate analysis
p-Value OR 95% CI p-Value
0.026a
0.014a
0.012a 0.197 0.044–0.890 0.035a
0.002a 15.209 1.185–195.195 0.037a
0.003a
0.012a
0.023a
0.019a 14.424 1.449–143.425 0.023a
0.033a 13.433 1.251–144.220 0.032a
gitis; CSF, cerebrospinal ﬂuid; LP, lumbar puncture.
Figure 1. Kaplan–Meier survival curves of HBV-infected patients and HBV-
uninfected patients with cryptococcal meningitis.
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increase the fungal burden.19 Hence, individuals in the HBV-
infected group were younger compared with the non-HBV-
infected group. These defects may also be associated with a
higher positive rate of Cryptococcus culture in CSF and more
extraneural involvement compared to HBV-uninfected patients.
Another important ﬁnding is the alteration in the neuroendo-
crine–immune system response in chronic viral hepatitis. Alter-
ation at any level of neuroendocrine control can modulate immune
function. Glucocorticoids play a crucial role in the interaction
between the neuroendocrine system and the immune system.20
Moreover, glucocorticoids have inhibitory effects on the inﬂam-
matory response. For example, glucocorticoids can inhibit the
production of some proinﬂammatory cytokines, such as IL-1 and
TNF, which can activate the central components of the central
stress circuit.21,22 It has been reported that HBV reactivation is
related to the intensity of immunosuppressive agents and the
increase in corticosteroid levels.23 In summary, the HBV-infected
patients may suffer a lower intensity of immune inﬂammation in
the pathogenesis of CM than those without HBV. This could explain
why more HBV-infected patients presented with lower CSF WBC
counts, lower percentages of total protein in the CSF exceeding
0.45 g/l (62.5% vs. 82.8%; p = 0.032), higher glucose in the CSF, and
normal brain imaging.
In this context, our results demonstrated no signiﬁcant
difference in mortality between HBV-infected and non-HBV-
infected patients. It is highly possible that this ﬁnding is due to
the small number of patients included in the study. As reported by
Lu et al.,12 we also found hydrocephalus to be an indicator of an
unsatisfactory outcome in HBV-uninfected patients with CM.
Moreover, we found that a lower CSF glucose level was also
associated with a poor prognosis in non-HBV-infected patients
with CM. Among the HBV-infected group, we concur with Jean
et al.24 – cirrhosis of the liver was found to be an independent risk
factor for a poor outcome in patients with cryptococcosis. Another
notable ﬁnding was that HBV DNA >1000 copies/ml was
associated with death or relapse of patients with CM. These
results can be explained by the speciﬁc immune deﬁcits that leadto cirrhosis in these patients, or to HBV reactivation being greater
in severity in these individuals than in others.
This study has some limitations. First, the study was performed
in a single hospital by retrospective review of the medical records.
Second, the presentations and prognoses vary depending on the
different serotypes of Cryptococcus, but further identiﬁcation was
not performed in this study. Third, the number of patients enrolled
was small, which may have led to an under-estimation of some of
the signiﬁcant factors. Further large multicenter studies are
needed in order to improve the generalizability of data on CM.
In summary, this study identiﬁed differences in the clinical
presentations, initial laboratory ﬁndings, and indicators of an
unsatisfactory outcome between HBV-infected patients and HBV-
uninfected patients with CM. It is necessary to note that those with
cirrhosis or HBV reactivation in the HBV-infected group had a poor
outcome; however such patients may present with low intensity
inﬂammation in the pathogenesis of CM.
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